CompletedPhase 3NCT06137092

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Studying Hemophilia A

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AryoGen Pharmed Co.
Principal Investigator
Aziz Eghbali, Assoc. Prof.
Iran University of Medical Sciences
Intervention
Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)(drug)
Enrollment
50 enrolled
Eligibility
12 years · MALE
Timeline
20232023

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06137092 on ClinicalTrials.gov

Other trials for Hemophilia A

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia A

← Back to all trials